{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018025","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.539148+00:00","generated_at":"2026-06-02T16:23:20.445403+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Oragenics partners with Avance Clinical for Phase II concussion trial of ONP-002 in Australia","bullets":["Phase II trial to evaluate ONP-002 for mild traumatic brain injury (concussion) delivered intranasally.","Phase I trial completed under Avance Clinical showed ONP-002 safe and well-tolerated.","Avance Clinical, a CRO with 20+ years experience, will manage the trial in Australia.","Oragenics President cites confident execution; CMO highlights Australia's head injury expertise.","Worldwide annual concussions estimated at 69 million; post-concussion syndrome occurs in up to 20%."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018025","json":"https://secwatch.observer/filing/0001493152-24-018025.json","markdown":"https://secwatch.observer/filing/0001493152-24-018025.md","text":"https://secwatch.observer/filing/0001493152-24-018025.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224018025/0001493152-24-018025-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224018025/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:23:20.445403+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}